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Abstract
Background: Alzheimer’s disease (AD) is caused by accumulation of Ab, which is produced through sequential cleavage of
b-amyloid precursor protein (APP) by the b-site APP cleaving enzyme (BACE1) and c-secretase. Enoxaparin, a low molecular
weight form of the glycosaminoglycan (GAG) heparin, has been reported to lower Ab plaque deposition and improve
cognitive function in AD transgenic mice.
Methodology/Principal Findings: We examined whether heparin and enoxaparin influence APP processing and inhibit Ab
production in primary cortical cell cultures. Heparin and enoxaparin were incubated with primary cortical cells derived from
Tg2576 mice, and the level of APP and proteolytic products of APP (sAPPa, C99, C83 and Ab) was measured by western
blotting. Treatment of the cells with heparin or enoxaparin had no significant effect on the level of total APP. However, both
GAGs decreased the level of C99 and C83, and inhibited sAPPa and Ab secretion. Heparin also decreased the level of b-
secretase (BACE1) and a-secretase (ADAM10). In contrast, heparin had no effect on the level of ADAM17.
Conclusions/Significance: The data indicate that heparin and enoxaparin decrease APP processing via both a- and b-
secretase pathways. The possibility that GAGs may be beneficial for the treatment of AD needs further study.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegener-
ative disease in the elderly and is a major cause of dementia [1,2].
AD is characterized by the deposition of amyloid plaques in the
brain [3,4], the major component of which is the b-amyloid
protein (Ab), a 40–42 amino-acid residue polypeptide [5,6] that is
generated from the b-amyloid precursor protein (APP) [7] by the
b-site APP cleaving enzyme-1 (BACE1) [8,9,10,11] and c-
secretase [12]. Cleavage of APP by BACE1 yields a C-terminally
truncated fragment (C99) which is subsequently cleaved by c-
secretase to yield at least two Ab species, the major product Ab40,
which contains 40-amino-acid residues and Ab42, which contains
an extra two amino-acid residues at its C-terminus. APP can also
be cleaved by a-secretase within the Ab sequence [13,14] to form
sAPPa and C83, which thus precludes formation of Ab [15].
Several members of the disintegrin and metalloprotease (ADAM)
family have been proposed as a-secretases although ADAM10 is
likely to be the most important contributor to this activity
[16,17,18,19]. Oligomeric forms of Ab are now thought to be the
major toxic species [20,21,22,23]. Therefore, therapeutically
targeting the production, aggregation, clearance or neurotoxicity
of Ab is a central theme of AD research [24].
A number of studies indicate that glycosaminoglycan (GAG)
may have value for the therapeutic treatment of AD. GAGs are
linear polymers consisting of repeated disaccharide units. Heparin
is a typical GAG and has a highly sulfated structure. A low
molecular weight (LMW) derivative of heparin, enoxaparin, is
generated by alkaline depolymerization of heparin benzyl ester.
Both heparin and LMW heparins have been widely used as
anticoagulant and antithrombotic drugs [25,26]. LMW heparins
are now generally regarded as safer and more effective for the
treatment of cardiovascular problems than unfractionated heparin
[27].
LMW GAGs may also be suitable agents for the treatment of
brain diseases as they can cross the blood-brain barrier [28,29].
GAGs can inhibit Ab toxicity [30,31,32,33] and may have
neuroprotective effects [34,35]. In addition, peripheral adminis-
tration of enoxaparin has been reported to reduce Ab load [32]
and improve cognition in APP transgenic mice [36]. The
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mechanism of these effects is unclear. GAGs bind directly to APP
[37,38,39,40] and may influence its function [41]. In addition,
GAGs can bind to aggregated Ab and accelerate amyloid fibril
formation [42,43].
Heparin may also influence Ab production by disrupting APP
proteolytic processing. Scholefield et al. [44] first reported that
heparan sulfate and heparin can directly inhibit BACE1 activity in
vitro and thereby decrease Ab production in cell culture. Our own
studies have shown that heparin binds close to the prodomain of
the BACE1 zymogen (proBACE1) and that this binding stimulates
proBACE1 activity [45,46]. However, heparin can also inhibit
mature BACE1 activity by binding close to the active site domain
of the mature protein [46]. In contrast to the results of Scholefield
et al. [44], Leveugle et al. [47] reported that heparin stimulates b-
secretase cleavage of APP in a cultured cell line.
As there are conflicting reports on the effect of GAGs on APP
processing and Ab production, we have examined the effects of
heparin and enoxaparin on APP processing in primary cortical
cells. We used cells obtained from transgenic mice expressing
human APP695 with the Swedish familial AD mutant (Tg2576
mouse) [48], because human APP and its fragments can be more
easily detected with existing anti-human antibodies than rodent
APP and Ab.
We report that heparin and enoxaparin lower Ab secretion
from cortical cells by decreasing BACE1 and thereby inhibiting b-
secretase processing of APP. This effect is not specific for
amyloidogenic processing of APP, as heparin and enoxaparin also
decrease the a-secretase ADAM-10 and inhibit a-secretase
processing of APP.
Results
Effect of heparin and enoxaparin on Ab
Initially, the effect of heparin and enoxaparin on the secretion of
Ab from cortical cells was examined. Primary cortical cells from
Tg2576 mice were cultured and then treated with heparin or
enoxaparin for 24 hours. The cell media were harvested and Ab
was immunoprecipitated from the medium and then detected by
western blotting. Although Ab40 was easily detected in the cell
culture medium, little Ab42 was observed (Fig. 1A). Therefore, in
the subsequent experiments, only the level of Ab40 was measured.
Ab40 and Ab42 were not detectable in the cell lysate (data not
shown). Incubations with 10 mg/mL and 100 mg/mL heparin
significantly lowered levels of Ab40 in the culture medium.
Enoxaparin also reduced the level of Ab40. However, enoxaparin
was less effective than heparin and only had a significant effect on
Ab40 at a concentration of 100 mg/mL (Fig. 1B).
Characterization of APP C-terminal fragments (CTFs)
To examine the effect of heparin and enoxaparin on APP
processing, we first characterized the major APP CTFs produced
by the Tg2576 mouse cortical cells. The cell lysates were analyzed
Figure 1. Effect of heparin (MH) and enoxaparin (ENO) on Ab secretion from Tg2576 mouse cortical cells. Cells were treated with 0, 1,
10, or 100 mg/mL heparin or enoxaparin for 24 hours. Ab40 and Ab42 in the culture medium were separated on Tris-bicine-urea SDS gels and
visualized by western blotting with anti-Ab monoclonal antibody 6E10. (A) Typical western blots showing the effect of heparin and enoxaparin on
Ab40. The position of pure recombinant human Ab40 (rAb40) and Ab42 (rAb42) is also shown. (B) Quantification of Ab40 immunoreactivity on the
western blots. Asterisks show values that are significantly different from control incubations containing no GAG (p,0.01, n = 9).
doi:10.1371/journal.pone.0023007.g001
Effect of GAGs on Ab Production
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by western blotting using a polyclonal anti-APP C-terminal
antibody.
Analysis of the cell lysate fraction revealed six discrete protein
bands migrating close to the 12-kDa molecular weight marker
(Fig. 2A, left panel). These bands corresponded to phospho-C99,
C99, phospho-C89, C89 (a product of cleavage adjacent to residue
11 in Ab by BACE1), phospho-C83 and C83, based on their
apparent molecular masses. To confirm their identities, the
membrane was stripped and reprobed using monoclonal antibody
6E10 which recognizes C99 but not C89 and C83. As expected,
we found that only the bands corresponding to phospho-C99 and
C99 were stained (Fig. 2A, right panel). Next, to confirm the
identification of the phospho-C99 band, the cell lysate protein was
immunoprecipitated with the anti-APP C-terminal antibody, and
immunoblotted using the same polyclonal anti-APP C-terminal
antibody (Fig. 2B, left panel). The membrane was then stripped
and restained using an anti-phospho-APP antibody UT33 which
recognizes APP fragments phosphorylated at threonine 668 of the
APP695 sequence [49]. Of the two 6E10-immunoreactive bands,
only the upper band was immunoreactive (Fig. 2B, right panel),
confirming that it was phospho-C99. Levels of phosphorylated
C89 and C83 were too faint to be easily visualised using UT33.
The identities of the APP CTFs were also confirmed using the c-
secretase inhibitor DAPT. DAPT has been shown previously to
cause the accumulation of both b- and a-secretase-derived CTFs
of APP (C99, C89 and C83) [50]. When primary cortical cells
were treated with DAPT for 24 hours, there was a large increase
in the levels of all protein bands around 12 kDa compared with
the control (Fig. 2C), confirming the identity of these bands as APP
CTFs.
Effect of heparin and enoxaparin on levels of APP, sAPPa
and CTFs
Next, the effect of heparin and enoxaparin on the levels of APP
and the APP CTFs was examined. Heparin and enoxaparin had
no significant effect on the level of full-length APP in the cell lysate
(Figs. 3A and B). However, heparin decreased the amount of
sAPPa secreted into the culture medium. Although 1 mg/mL
heparin did not significantly decrease the level of sAPPa, higher
concentrations (10 and 100 mg/mL) of heparin significantly
reduced sAPPa immunoreactivity by 40% and 50%, respectively
(Figs. 3C and D). Enoxaparin had a similar effect as heparin, but
was less effective in its ability to reduce sAPPa. Enoxaparin (10
and 100 mg/mL) reduced the sAPPa immunoreactivity by
approximately 25% and 30%, respectively.
Subsequently, the effects of heparin and enoxaparin on C99 and
C83 were determined. Cell lysates were analyzed by western
blotting using the anti-APP C-terminal antibody or the anti-Ab
monoclonal antibody 6E10. Although C99 was clearly visualized
using this method, the level of C83 was too low to measure
accurately. Therefore, only C99 was quantified. C99 and
phospho-C99 were measured together as they were often poorly
separated. Heparin decreased C99 in a dose-dependent manner.
At concentrations between 1 and 100 mg/mL, heparin lowered
C99 immunoreactivity by between 25% and 75% (Figs. 3E and F).
Enoxaparin also decreased the level of C99, but it was less potent
in this regard. Enoxaparin, at concentrations of 10 and 100 mg/
mL, significantly reduced C99 immunoreactivity by 30% and 50%
of the control value, respectively.
As heparin and enoxaparin decreased levels of C99, we
examined whether this decrease might be attributed to an increase
in c-secretase activity, or to a decrease in C99 production. In the
presence of the c-secretase inhibitor DAPT (0.5 mM), it was
possible to accurately quantify C83 levels. Heparin (1 mg/mL) had
no significant effect on the level of C99. However, 10 and 100 mg/
mL heparin reduced C99 immunoreactivity by approximately
40% and 55%, respectively (Figs. 4A and B) and heparin (10 and
100 mg/mL) decreased C83 immunoreactivity by approximately
40% and 60% (Fig. 5). In the presence of DAPT, enoxaparin (1
and 10 mg/mL) did not significantly decrease C99 or C83.
However, 100 mg/mL enoxaparin decreased both C99 and C83 to
approximately 50% of control values (Fig. 4, Fig. 5). Taken
together, the results demonstrated that the reduced secretion of Ab
was due to the decreased level of C99, and that treatment with
heparin and enoxaparin also decreased a-secretase processing.
Figure 2. Characterization of APP C-terminal fragments in Tg2576 mouse cortical cells. (A) Cell lysates from Tg2576 primary cortical cells
at 7 DIV were analysed on 16.5% Tris-tricine SDS-PAGE and immunoblotted with polyclonal anti-APP C-terminal antibody (left). Membranes were
stripped and reprobed with monoclonal antibody 6E10 which recognises the N-terminal region of Ab (right). (B) Cell lysates were
immunoprecipitated using the anti-APP C-terminal antibody, and then separated on 16.5% Tris-tricine polyacrylamide gels. After blotting APP
CTFs were visualized with the anti-APP C-terminal antibody (left). Blots were then stripped and reprobed with UT33 (right), an antibody which
recognizes phosphorylated APP. (C) Cells were incubated in the absence (control) or presence of 0.5 mM DAPT for 24 hours. Cell lysates were resolved
on 16.5% Tris-tricine polyacrylamide gels. After blotting, the APP CTFs were visualized with the anti-APP C-terminal antibody. The positions of C99,
C89 and C83 as well as their phosphorylation forms (P-C99, P-C89 and P-C83) are indicated.
doi:10.1371/journal.pone.0023007.g002
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Effect of heparin on the level of b-secretase (BACE1) and
a-secretase (ADAM10 and ADAM17)
To examine whether the decrease in a- and b-secretase processing
of APP was due to a reduction in the level of a- and b-secretase,
primary cortical cells were treated with heparin (100 mg/ml) for 24 hr
and then the cells were lysed and the level of b-secretase (BACE1) and
two putative a-secretases (ADAM10 and ADAM17) were measured
in the cell lysate by western blotting. Heparin (100 mg/ml)
significantly decreased the level of BACE1 and ADAM10 to
approximately 50% and 25% of control values (Fig. 6A–C).
However, incubation with heparin did not lead to a significant
change in ADAM17 levels compared with controls (Fig. 6A and D).
Effect of heparin fragments on Ab secretion
As there were significant differences between heparin and
enoxaparin in their effects on APP metabolism and Ab
Figure 3. Effects of heparin (MH) and enoxaparin (ENO) on APP (A, B), sAPPa (C, D) and C99 (E, F) in Tg2576 mouse cortical cell
cultures. Cells were treated with 0, 1, 10, 100 mg/mL heparin or enoxaparin for 24 hours. Figure shows typical western blots illustrating the effect of
MH and ENO on APP (A), sAPPa (C) and C99 (E). b-Actin immunoreactivity is shown as a loading control. Figure also shows quantification of the level
of APP (B), sAPPa (D) and C99 (F) immunoreactivity. Asterisks show values that are significantly different from controls (p,0.05, n = 12).
doi:10.1371/journal.pone.0023007.g003
Effect of GAGs on Ab Production
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production, and because enoxaparin is comprised of a mixture of
small-sized heparin fragments [26], we examined the effect of
heparin fragments of different molecular weight on secretion of
Ab. Primary cortical cells from Tg2576 mice were cultured and
then treated with 18 kDa heparin, 5 kDa heparin, 3 kDa heparin
or enoxaparin for 24 hours. The cell culture medium was
harvested and Ab was immunoprecipitated from the medium
and detected by western blotting. Incubations with native 18 kDa
heparin, 5 kDa heparin, 3 kDa heparin or enoxaparin significant-
ly lowered levels of Ab40 in the culture medium. However, 5 kDa
heparin, 3 kDa heparin and enoxaparin were less effective
compared with native heparin (Fig. 7).
Discussion
In this study, the effect of heparin and enoxaparin on APP
processing and Ab production was examined in primary cortical
cells obtained from APP Tg2576 mice. The study showed that
while heparin and enoxaparin had no effect on the level of full-
length APP, they decreased the level of C99, C83, sAPPa and
secreted Ab in a dose-dependent manner. Heparin also decreased
the level of b-secretase (BACE1) and a putative a-secretase
(ADAM10) but had no effect on the level of another putative
a-secretase (ADAM17).
As the level of total APP was not decreased by heparin or
enoxaparin, the decreased levels of C99, Ab, sAPPa and C83 were
not due to a decrease in full-length APP. Furthermore, as heparin
and enoxaparin decreased the level of C83 and C99 in the
presence of a c-secretase inhibitor, this indicated that the effect of
GAGs in decreasing C99 and C83 could not be due to an increase
in c-secretase activity.
We speculated that the decrease in C99, C83 and the decrease
in Ab secretion might be due to a decrease in the level of a- and b-
secretases. Therefore, we measured the level of both a- and b-
secretases by western blotting. Our results showed that heparin
significantly decreased the level of BACE1 and ADAM10, which
has been shown to be the major contributor to total a-secretase
activity in many cells [19]. In contrast, the level of another putative
a-secretase, ADAM17 was not changed in the presence of heparin.
Therefore, the results demonstrate that the GAG-induced
decrease in Ab secretion and the reduction in C99 were most
likely due to a decrease in BACE1 levels within the cortical cells.
The mechanism by which GAGs lower levels of BACE1 and
ADAM10 is unclear. As BACE1 may bind to endogenous
proteoglycans and because this interaction may be important for
the trafficking [44] or processing of BACE1 [45], it is possible that
heparin and enoxaparin may disrupt the normal trafficking or
processing of the enzyme. However, it is unclear whether such a
Figure 4. Effects of DAPT, heparin and enoxaparin on C99 levels in Tg2576 mouse cortical cells. (A) Cells were incubated in the absence
(control), or presence of 0.5 mM DAPT and in the absence or presence of 1 mg/mL heparin (MH1), 10 mg/mL heparin (MH10) or 100 mg/mL heparin
(MH100), 1 mg/mL enoxaparin (ENO1), 10 mg/mL enoxaparin (ENO10) or 100 mg/mL enoxaparin (ENO100) for 24 hours. The cell lysates were analysed
for C99. b-Actin immunoreactivity is shown as a loading control. Chemiluminescence was detected with either short exposures (short exp.) or long
exposures (long exp.) to visualise different levels of C99. (B) Quantitative analysis of C99 immunoreactivity. Asterisks show values that are significantly
different from controls (p,0.01, n = 9).
doi:10.1371/journal.pone.0023007.g004
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Figure 5. Effects of heparin and enoxaparin in the presence of 0.5 mM DAPT on C83 in Tg2576 mouse cortical cells. (A) Cells were
incubated in the presence or absence of 1, 10 or 100 mg/mL heparin (MH1, MH10 or MH100, respectively) or 1, 10 or 100 mg/ml enoxaparin (ENO1,
ENO10 or ENO100, respectively) for 24 hours. Cell lysates were then analysed by western blotting using polyclonal anti-APP C-terminal antibody to
determine the level of C83. The level of b-actin immunoreactivity was used as a loading control. (B) Quantification of the level of C83
immunoreactivity. Asterisks show values that are significantly different from controls (p,0.001, n = 9).
doi:10.1371/journal.pone.0023007.g005
Figure 6. Effect of heparin (MH) on the level of BACE1, ADAM10 and ADAM17 in Tg2576 mouse cortical cell cultures. Cells were
treated with 100 mg/mL MH for 24 hours. Figure shows typical western blots illustrating the effect of MH on BACE1, ADAM10 and ADAM17 (A).
b-Actin immunoreactivity is shown as a loading control. Figure also shows quantification of the level of BACE1 (B), ADAM10 (C) and ADAM17 (D)
immunoreactivity. Asterisks show values that are significantly different from controls (p,0.05, n = 8).
doi:10.1371/journal.pone.0023007.g006
Effect of GAGs on Ab Production
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mechanism can also explain the effect of heparin on ADAM10
levels. Furthermore, it was interesting to note that the structurally
related enzyme ADAM17 was not affected by heparin. To date,
there have been no reports that ADAM10 can interact with GAGs
or proteoglycans, although this possibility cannot be ruled out.
GAGs could conceivably exert a less direct effect on BACE1 and
ADAM10, possibly by acting on a specific secretory pathway. In
this regard, it is interesting to note that there are differences in the
roles of ADAM10 and ADAM17 in membrane protein shedding
[51]. ADAM17 can be stimulated by protein kinase C and may be
part of a regulated secretion pathway [52], whereas ADAM10
may be associated with a constitutive secretion pathway [53]. APP
can be processed via both pathways [15,16,54]. Thus it is tempting
to speculate that GAGs may selectively alter the level of enzymes
in the constitutive secretion pathway, rather than the regulated
pathway, thus accounting for the selective decrease in ADAM10
but not in ADAM17.
We found that the smaller sized enoxaparin was less efficient in
its ability to inhibit APP processing to Ab than native full-length
heparin. To examine the reason for this difference, we compared
18 kDa native heparin and enoxaparin with heparins of defined
molecular weight. We found that low molecular weight (3 kDa
and 5 kDa) heparins were less effective in inhibiting the secretion
of Ab than native heparin (Fig. 7). Enoxaparin possesses an
average molecular weight of approximately 4.5 kDa and its
efficacy for inhibiting Ab secretion was similar to that of 5 kDa
heparin. Therefore, this result suggests that the differences
between heparin and enoxaparin are probably due to differences
in molecular weight.
In a previous preliminary study, we reported that heparin could
decrease the level of Ab and sAPPa in cortical cells [55]. However,
in that study, we did not observe any effect of heparin on C99 or
C83. Our failure to observe an effect on C99 and C83 previously
was possibly due to the fact that the number of replicates in the
earlier experiments was too low to observe significant differences
in C99 and C83 levels. In a previous study, Scholefield et al. [44]
reported that heparin and heparin analogues inhibit Ab and
sAPPb generation in APP-expressing cells, and they drew the
conclusion that GAGs may bind to BACE1 and inhibit BACE1
cleavage activity. Our own studies have shown that at low
concentrations (e.g. 1 mg/ml) GAGs stimulate the activity of the
zymogen pro-BACE1 whereas at higher concentrations (e.g.
100 mg/ml) they inhibit the activity of the mature enzyme [45].
This biphasic effect of GAGs is most simply explained by the
presence of a single heparin-binding site that lies adjacent to the
both the pro sequence and active site regions [46]. Low
concentrations of GAGs can alter the conformation of the
prodomain, but higher concentrations are needed to block the
active site [46].
In contrast to our study, Leveugle et al. [47], using SH-SY5Y
neuroblastoma cells overexpressing APP with the Swedish
mutation, reported that GAGs can increase APP secretion and
processing through the b-secretase pathway. The difference in the
effect of GAGs between the study of Leveugle et al. [47] and our
own data is unclear, but it may possibly be explained by the fact
that APP processing occurs differently in neuroblastoma cells
overexpressing APP compared with primary cortical cells. This
possibility emphasizes the need to use primary cells in culture,
rather than cell lines for these types of studies.
Interestingly, we found that, in the absence of the c-secretase
inhibitor DAPT, C99 was more abundant than C83. This finding
contrasts with reports from many studies using APP-transfected
cells that C83 is more abundant than C99 [56,57], in keeping with
the concept that the a-secretase pathway is a predominant route of
APP processing than the b-secretase pathway. However, the
observation that C99 was present in higher abundance than C83 is
consistent with some previous studies in both APP23 and Tg2576
mice [58,59,60]. One possible explanation for the high level of
C99 in the Tg2576 cells is that the transgene possesses the human
Swedish NL double mutation at the beginning of the Ab encoding
region. This mutation increases the susceptibility of APP for
cleavage by BACE1 [61,62]. Another reason why the level of C99
may have been higher than C83 is that the relative rate of cleavage
of C99 and C83 by c-secretase may be different. The level of C99
and C83 depends, in part, on the relative rates of a- and b-
secretase cleavage of APP [15]. However, it may also depend upon
the capacity of the cells for c-secretase cleavage. It has been
reported that the c-secretase degrades C83 much quicker than
C99 [60]. Under conditions in which the c-secretase is not
saturated with its substrate, the relative rates of cleavage of C83
and C99 by c-secretase may greatly influence the level of total C83
or C99. However, under conditions of very high APP overexpres-
sion, or under conditions where c-secretase is almost completely
inhibited, the c-secretase would be saturated and the relative
proportions of C99 and C83 would be dependent solely upon the
relative rates of b- and a-secretase cleavage, respectively. In
support of this idea, we found that in the presence of the c-
secretase inhibitor DAPT, the proportion of C83 relative to C99
increased greatly.
In summary, our experiments demonstrate that GAGs alter
APP metabolism and decrease secretion of Ab. Low molecular
weight heparins have also been shown to cross the blood-brain
barrier [28,29], to arrest amyloid-induced inflammation [63,64],
to decrease Ab aggregation [64] and to lower the Ab generation
and improve cognition in AD transgenic mice [32,36]. Therefore,
our data provide support for the view that heparin analogues may
have value for the treatment of AD. However, it is worth
considering the possibility that heparin analogues may have toxic
side effects which lower their value as therapeutic agents. Our
study found that GAGs inhibited a-secretase processing of APP,
and this effect was associated with a decrease in the level of
ADAM10. A number of studies have suggested that sAPPa may
have important trophic functions [65]. Thus inhibition of sAPPa
production could produce adverse effects in vivo. Such a possibility
needs to be considered when examining the potential of heparin
analogues for the treatment of AD.
Figure 7. Effect of heparin fragments of different molecular
weight on Ab secretion from Tg2576 mouse cortical cells. Cells
were treated with 100 mg/mL 18 kDa heparin, 5 kDa heparin, 3 kDa
heparin or enoxaparin for 24 hours. Ab40 and Ab42 in the culture
medium were visualized by western blotting using monoclonal
antibody 6E10. Figure shows the quantification of Ab40 immunoreac-
tivity on the western blots. Asterisks show values that are significantly
different from each other (p,0.01, n = 8).
doi:10.1371/journal.pone.0023007.g007
Effect of GAGs on Ab Production
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Materials and Methods
Materials
Porcine mucosal heparin, 5 kDa heparin, 3 kDa heparin,
monoclonal anti-b-actin antibody, rabbit anti-BACE1 (EE-17)
antibody, polyclonal anti-APP C-terminal antibody (APP-CT) and
N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl
ester (DAPT) were purchased from Sigma-Aldrich Pty. Ltd.
(Sydney, Australia). Rabbit anti-ADAM10 (ab1997) and rabbit
anti-ADAM17 (ab2051) were purchased from Sapphire Bioscience
Pty. Ltd. (Waterloo, Australia). Monoclonal anti-Ab antibody
6E10 was from Covance Pty. Ltd. (North Ryde, Australia).
Neurobasal medium and B27 supplement were purchased from
Invitrogen (Mulgrave, Australia). Mouse and rabbit HRP-
conjugated secondary antibodies were purchased from DAKO
(Campbellfield, Australia). Enoxaparin sodium (ClexaneH) was
from Sanofi-Aventis (Macquarie Park, Australia). Protein G
Sepharose and complete mini protease inhibitor cocktail tablet
were purchased from Roche Diagnostics (Castle Hill, Australia). A
polyclonal anti-phosphorylated APP antibody UT33 was prepared
as previously described [49].
Cell culture
Cortical cells were prepared from newborn (P0) Tg2576
mouse. Cerebral cortices were dissected and incubated in Ca2+-
and Mg2+-free Hank’s balanced salts (HBSS) containing 0.25%
(w/v) papain and 0.06% (w/v) deoxyribonuclease I (DNase I) for
30 min at 37uC, followed by three washes with neurobasal
medium. Cells were then separated by gentle mechanical
dissociation and 36105 cells were plated onto poly-D-lysine-
coated 12-well culture plates, and maintained in 1.2 mL complete
neurobasal medium containing 2% B27 supplement, 1 mM
glutamine, and 1% penicillin/streptomycin (10,000 units of
penicillin and 10,000 mg of streptomycin stock) in an atmosphere
containing 5% CO2 at 37uC. After 3 days in vitro (DIV), half of
the culture medium was replaced with fresh complete neurobasal
medium. All experiments were performed at 7 DIV cultures.
Primary cortical cells were incubated with GAGs and inhibitors
for 24 hours prior to sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE).
SDS-PAGE and western blotting
After treatment with GAGs or drugs, the medium was removed
from cells for determination of Ab and sAPPa. The cells were
incubated with cold RIPA buffer (150 mM NaCl, 50 mM Tris,
0.5% w/v Na-deoxycholate, 1% v/v Nonidet P-40, 0.1% SDS,
pH 7.4) containing protease inhibitor cocktail on ice for 10 min
and the cell lysates were then harvested for determination of C99,
C83,BACE1, ADAM10, ADAM17 and full-length APP.
The amount of Ab40 or Ab42 secreted into cell medium was
determined on 15% Tris-bicine-urea SDS-PAGE gels as described
previously [66]. The cell medium was collected and cell debris was
removed by centrifugation at 500 g for 5 min. The supernatant
fractions were then transferred to 1.5 mL Eppendorf tubes.
Monoclonal antibody 6E10 (1:1667 v/v) was added and the
mixture was incubated overnight at 4uC. Protein G agarose (20 mL
hydrated gel/mL medium) was then added and incubated for a
further 3 hours at 4uC. The beads were washed 3 times in 1 mL
cold phosphate-buffered saline (PBS), and then 30 mL of sample
buffer was added to each pellet. After gentle mixing, the slurry was
heated for 5 min at 95uC. The sample was then centrifuged for
10 min at 15,000 rpm and 30 mL supernatant fraction was loaded
on 15% Tris-bicine-urea gels. After electrophoresis, proteins were
transferred onto a polyvinylidene difluoride (PVDF) membrane
and stained with monoclonal antibody 6E10 (1:2,000 dilution) for
Ab.
For the determination of sAPPa, BACE1, ADAM10, ADA-
M17and full-length APP, cell medium (the loading volumes were
normalized from protein concentration of cell lysates) or 8 mg
protein cell lysate were applied to 8% Tris-glycine SDS-PAGE
gels and subjected to western blotting using the anti-Ab
monoclonal antibody 6E10 (1:2,000 dilution), anti-ADAM10
polyclonal antibody (1:1,000 dilution), anti-BACE1 polyclonal
antibody (1:1,000 dilution), anti-ADAM17 polyclonal antibody
(1:1,000 dilution) or an anti-b-actin monoclonal antibody
(1:16,000 dilution). The protein concentration was measured
using the Bio-Rad DC protein assay kit (Bio-Rad Laboratories
Pty. Ltd., Gladesville, Australia) with bovine serum albumin as
standard.
To determine the level of C99 and C83 in cells, cell lysates
containing 12 mg of protein were applied to 16.5% Tris-tricine
SDS-PAGE gel. After electrophoretic transfer of proteins onto a
PVDF membrane, the membrane was cut into two pieces at the
position of the 24 kDa molecular weight marker. The piece of
PVDF membrane containing proteins from the upper region of
the gel which migrated above an apparent molecular mass of
24 kDa was stained using a monoclonal antibody directed against
b-actin (1:16,000 dilution), and the piece containing proteins from
the lower region of the gel which migrated below 24 kDa was
stained for C99 and C83 using a polyclonal anti-APP C-terminal
antibody (1:2,000 dilution), which was raised against residues 676–
695 of the APP695 sequence.
For all western blotting, the bound primary antibody was
detected using either a polyclonal goat anti-mouse or an anti-
rabbit immunoglobulin conjugated to horseradish peroxidase
(HRP) (1:6,000 dilution) and ImmobilonTM Western chemilumi-
nescent HRP substrate from Millipore Pty. Ltd. (North Ryde,
Australia). Chemiluminescence was detected using a Chemi-Smart
5000 gel documentation system (Vilber Lourmat, Torcy, France).
Images were taken and the density of staining was quantified using
Image J software (RSB; NIH, http://rsbweb.nih.gov/ij/index.
html). The ratio of immunoreactivity for each protein to the b-
actin immunoreactivity was determined and then each ratio was
used to calculate a percentage relative to mean values for control
incubations lacking GAG. All experiments were performed at least
six times and statistical tests were performed using SigmaPlot
software (10.0v; Systat Software, Inc., San Jose, CA, USA).
Statistical comparisons were made using one-way analysis of
variance and Student’s t tests. Values of p,0.05 were considered
statistically significant.
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